Results 71 to 80 of about 2,265 (188)

Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment [PDF]

Severe asthma (SA) is a chronic inflammatory condition affecting approximately 10% of asthmatic patients, and eosinophils are considered key pathogenetic actors in a significant number of patients.
D'Aiuto V., de Paulis A., Della Casa F., Granata F., Mignogna G., Mormile I., Romano A., Rossi F. W.   +7 more
core   +1 more source

Early and Sustained Asthma Control and Remission in Real‐World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC‐2

Clinical &Experimental Allergy, EarlyView.
Real‐world patients with severe eosinophilic asthma treated with benralizumab showed early and sustained improvements in symptoms. Clinically meaningful improvements began as early as one week after benralizumab initiation, regardless of previous biologic use, and further improved over the following year.
Erika Penz, Thomas Rothe, Lieven Dupont, Trung N. Tran, Andrew Menzies‐Gow, Anat Shavit, David Cohen, Tanja Plate, Sheena Kayaniyil, An Herreman, Claudio Schuoler, Benjamin Emmanuel, Marek Lommatzsch   +12 more
wiley   +1 more source

Comparative efficacy and safety of monoclonal antibodies biologic therapies for chronic rhinosinusitis with nasal polyps: A systematic review and network meta-analysis

American Journal of Otolaryngology
Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a significant therapeutic challenge with high recurrence rates despite the current standard treatments.
Abdulhakeem Almutairi, Lina Yousef Aloraini, Bader Muzhier Alshahrani, Maan Omar Alzuhairi, Rabab Hussain Alzanadi, Khalid Fahad Alanazi, Yahya Ali Khubrani, Ahmed Y. Azzam   +7 more
doaj   +1 more source

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR

Journal of Asthma and Allergy, 2023
Tanya M Laidlaw1,2 *, Andrew Menzies-Gow3 *, Scott Caveney,4 Joseph K Han,5 Nicole Martin,6,7 Elliot Israel,8 Jason K Lee,9,10 Jean-Pierre Llanos,11 Neil Martin,12,13 Ayman Megally,14 Bhavini Parikh,14 Sylvia Vong,15 Tobias Welte,16 Jonathan ...
Laidlaw TM, Menzies-Gow A, Caveney S, Han JK, Martin N, Israel E, Lee JK, Llanos JP, Martin N, Megally A, Parikh B, Vong S, Welte T, Corren J   +13 more
doaj  

Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential. [PDF]

Thymic stromal lymphopoietin (TSLP) is a member of the IL-2 cytokine family and has been widely recognized as a master regulator of type 2 inflammatory responses at barrier surfaces.
Du, Kehe, Han, Jianzhong, Huang, Jian, Jiang, Fengchao, Li, Li, Liu, Hongjun, Liu, Xiaolei, Wang, Peng, Wang, Qian, Zhang, Pei   +9 more
core   +2 more sources

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 782-790, March 2026.
Verekitug, a novel, high‐affinity, fully human monoclonal antibody targeting thymic stromal lymphopoietin receptor (TSLPR), is in development as a potential treatment for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Dave Singh, Chaim M. Brickman, Peter Lloyd, Ashish Kalra, Subhabrata Biswas, Arkadeep Sinha, Alex Mulvanny, Sumathi Sivapalasingam, Oren M. Becker, Aaron Deykin   +9 more
wiley   +1 more source

Importance of Smell Loss to Patients With Chronic Rhinosinusitis With Nasal Polyps: Options for Management and Recovery

Clinical and Translational Allergy, Volume 16, Issue 2, February 2026.
ABSTRACT Primary diffuse type 2‐dominant chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease of the nasal cavity and paranasal sinuses associated with significant morbidity. Impaired sense of smell is a cardinal symptom of CRSwNP and one of the most burdensome for patients, impacting quality of life, mental health, and even ...
Thomas S. Higgins, Jennifer E. Douglas, Robert C. Kern, James N. Palmer, Sietze Reitsma, Martin Wagenmann, Rhea Goodman, Mark Corbett, Cristina Almansa, Amr Radwan   +9 more
wiley   +1 more source

Distinguishing Features of ILC2s During Type 2 Immune Responses

European Journal of Immunology, Volume 56, Issue 2, February 2026.
Group 2 innate lymphoid cells (ILC2s) are tissue‐resident cells regulated by diverse signals often emanating from surrounding nonhematopoietic cells at barrier surfaces. Their effector cytokines determine tissue homeostasis at steady state and during type 2 immunity in allergies or worm infections.
Manuel O. Jakob, Patrycja M. Forster, Christoph S. N. Klose   +2 more
wiley   +1 more source

Current Insights Into Individualized Diagnosis and Treatment of Allergic Rhinitis Based on Phenotype and Endotype

World Journal of Otorhinolaryngology - Head and Neck Surgery, Volume 12, Issue 1, Page 124-135, February 2026.
ABSTRACT Allergic rhinitis (AR) is a chronic inflammatory disease of the nasal mucosa characterized by allergen sensitization and the involvement of multiple inflammatory mediators. Currently, the treatment of AR mainly includes symptomatic relief, anti‐inflammatory therapy, and nerve desensitization. However, these treatments have limitations in fully
Yue Gu, Long‐Lan Shu, Tao Lu, Da‐Yu Guan, Bo‐Wen Zheng, Pan‐Hui Xiong, Yang Shen, Yu‐Cheng Yang   +7 more
wiley   +1 more source

Real‐World Treatment Patterns in AERD: An Analysis of ATAD, Biologics, and Combination Therapy

International Forum of Allergy &Rhinology, Volume 16, Issue 1, Page 99-101, January 2026.
Key Points Contemporary aspirin exacerbated respiratory disorder (AERD) therapy commonly includes aspirin desensitization (55%) and biologics (48%). Aspirin desensitization therapy has higher discontinuation rates than biologics. Patients receiving biologics are younger, and ∼25% of the patients switch to other agents.
Nitish Kumar, Tyson Pace, Pedro Lança Gomes, Michael J. Marino, Amar Miglani, Devyani Lal   +5 more
wiley   +1 more source